Cell cycle deregulation in B-cell lymphomas

被引:285
|
作者
Sánchez-Beato, M [1 ]
Sánchez-Aguilera, A [1 ]
Piris, MA [1 ]
机构
[1] CNIO, Mol Pathol Program, Lymphoma Grp, E-28029 Madrid, Spain
关键词
D O I
10.1182/blood-2002-07-2009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Disruption of the physiologic balance between cell proliferation and death is a universal feature of all cancers. In general terms, human B-cell lymphomas can be subdivided. into 2 main groups, to low- and high-growth fraction lymphomas, according to the mechanisms through which this imbalance is achieved. Most types of low-growth fraction lymphomas are initiated by molecular events resulting in the inhibition of apoptosis, such as translocations affecting BCL2, in follicular lymphoma, or BCL10 and API2/MLT1, in mucosa-associated lymphoid tissue (MALT) lymphomas. This results in cell accumulation as a consequence of prolonged cell survival. In contrast, high-growth fraction lymphomas are characterized by an enhanced proliferative activity, as a result of the deregulation of oncogenes with cell cycle regulatory functions, such as BCL6, in large B-cell lymphoma, or c-myc, in Burkift lymphoma. Low- and high-growth fraction lymphomas are both able to accumulate other alterations in cell cycle regulation, most frequently involving tumor suppressor genes such as p16(INK4a), p53, and p27(KIP1). As a consequence, these tumors behave as highly aggressive lymphomas. The simultaneous inactivation of several of these regulators confers in creased aggressivity and proliferative advantage to tumoral cells. In this review we discuss our current knowledge of the alterations in each of these pathways, with special emphasis on the deregulation of cell cycle progression, in an attempt to integrate the available information within a global model that describes the contribution of these molecular changes to the genesis and progression of B-cell lymphomas. (C) 2003 by The American Society of Hematology.
引用
收藏
页码:1220 / 1235
页数:16
相关论文
共 50 条
  • [31] Primary Cutaneous B-Cell Lymphomas
    Inhoff, O.
    Dippel, E.
    AKTUELLE DERMATOLOGIE, 2011, 37 (1-2) : 47 - 55
  • [32] MicroRNA signatures in B-cell lymphomas
    L Di Lisio
    M Sánchez-Beato
    G Gómez-López
    M E Rodríguez
    S Montes-Moreno
    M Mollejo
    J Menárguez
    M A Martínez
    F J Alves
    D G Pisano
    M A Piris
    N Martínez
    Blood Cancer Journal, 2012, 2 : e57 - e57
  • [33] Immunotoxins for the treatment of B-cell lymphomas
    Ghetie, MA
    Ghetie, V
    Vitetta, ES
    MOLECULAR MEDICINE, 1997, 3 (07) : 420 - 427
  • [34] Primary cutaneous B-cell lymphomas
    Slater, D
    ARCHIVES OF DERMATOLOGY, 1997, 133 (12) : 1604 - 1605
  • [35] DOUBLE HIT B-CELL LYMPHOMAS
    Obukhova, T.
    Baryakh, E.
    Lorie, Y.
    Alimova, G.
    Kleina, I.
    Chernysh, S.
    Petrova, G.
    Kolosheinova, T.
    Magomedova, A.
    Parovichnikova, E.
    Kovrigina, A.
    Domracheva, E.
    HAEMATOLOGICA, 2012, 97 : 283 - 283
  • [36] Pretargeted radioimmunotherapy for B-Cell lymphomas
    Green, Damian J.
    Pagel, John M.
    Pantelias, Anastasia
    Hedin, Nathan
    Lin, Yukang
    Wilbur, D. Scott
    Gopal, Ajay
    Hamlin, Donald K.
    Press, Oliver W.
    CLINICAL CANCER RESEARCH, 2007, 13 (18) : 5598S - 5603S
  • [37] MONOCYTOID B-CELL LYMPHOMAS - REPLY
    SHEIBANI, K
    TRAWEEK, ST
    SHIN, SS
    BENEZRA, J
    STROUP, R
    ESTEBAN, J
    RAPPAPORT, H
    BATTIFORA, H
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1990, 14 (09) : 890 - 891
  • [38] Primary Cutaneous B-cell Lymphomas
    Hope, Charity B.
    Pincus, Laura B.
    CLINICS IN LABORATORY MEDICINE, 2017, 37 (03) : 547 - +
  • [39] PRIMARY CUTANEOUS B-CELL LYMPHOMAS
    RIJLAARSDAM, JU
    WILLEMZE, R
    LEUKEMIA & LYMPHOMA, 1994, 14 (3-4) : 213 - 218
  • [40] Immunotoxins for the Treatment of B-Cell Lymphomas
    Maria-Ana Ghetie
    Victor Ghetie
    Ellen S. Vitetta
    Molecular Medicine, 1997, 3 : 420 - 427